Reference entry · Acylated amylin receptor agonist
Cagrilintide
Also known as: Long-acting amylin analog · AM833
- Class
- Acylated amylin receptor agonist
- Primary targets (literature)
- Amylin (and calcitonin receptor complexes in literature)
- Regulatory context
- Investigational — not FDA-approved as a standalone catalog peptide for human use.
Overview
Cagrilintide is a long-acting amylin analog studied in combination with GLP-1 agonists in metabolic research programs. It extends the incretin research arc with amylin-pathway biology distinct from GLP-1 alone.
Mechanism in research literature
Amylin receptor agonism influences satiety signaling, gastric emptying, and glucagon suppression in research models — combined with GLP-1 agonists in sponsor-led trials.
Common research focus areas
- Combination trials with semaglutide
- Amylin vs. incretin pathway comparison
- Acylation and exposure profiles
- Development-stage evidence maturity
Full literature roundup
Read the cited research summary
A long-acting amylin analog studied alongside GLP-1 agonists in metabolic research. Mechanism, literature, and quality considerations.
Cagrilintide research roundup · 5 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.